Aroa Biosurgery share price jumps 8% on approvals

The Aroa Biosurgrey share price has jumped 8% following the company's announcement the FDA and European Union approved two of its products.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Aroa Biosurgery Ltd (ASX: ARX) share price has closed 7.69% higher today after announcing it has secured United States Food and Drug Administration (FDA) clearance for one of its products, 'Symphony'. In addition, the company received European approval for its product, 'Myriad', and released an investor presentation today.

The New Zealand-based Aroa is a soft tissue regeneration company focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. 

Symphony FDA clearance

Symphony is designed to reduce complex wound healing time in the proliferative phase where normal healing is impaired due to disease.

Its pending commercial launch in 2021 presents a major expansion in Aroa's product portfolio in the US. Pleasingly, the launch will take the company's addressable market to more than $2.5 billion, up from $1.5 billion previously.

Aroa CEO Brian Ward said "Symphony will give clinicians a new option to treat some of their most hard to heal patients, in what we estimate is a US market size of US$1.15 billion for the product".

European approval for Myriad

Aroa's product, Myriad, has received the 'CE mark' to allow commercialisation in the European Union. Myriad supports rapid tissue growth for dermal tissue reconstruction. The company expects the launch of the product to occur in 2021. 

The FDA clearance in June 2017 led to first sales earlier this year. Additionally, it is estimated the total addressable market size for the product globally is US$350 million.

July investor presentation

According to its investor presentation, all Aroa's products are based on its proprietary Endoform platform technology which is a unique Extracullular Matrix (ECM) derived from sheep forestomach.

Additionally, the company says its technology offers superior regenerative performance at a significantly lower cost than other biologics enabling more patients to have access to the benefits of regenerative healing.

The company's products have competitor protection due to the patents it owns. This includes 10 patents and 25 pending patent applications across 6 patent families. Aroa has 5 patented products selling across the US alone.

Pleasingly, the company's revenue has grown from $8.43 million in FY18 to $21.92 million in FY20. Furthermore, its product gross margin of 71% in FY20 has expanded compared to 36% in FY18. It is earnings before tax, depreciation and amortisation (EBITDA) positive in FY20 on a proforma basis.

Aroa Biosurgery share price performance

The Aroa Biosurgery share price closed today's trade at $1.54 which represents a 14.07% increase since it listed on the ASX just last Friday.

Motley Fool contributor Matthew Donald has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Broker Notes

How this undervalued ASX All Ords share could rocket 80% in a year

A leading fund manager expects a big turnaround for this beaten-down ASX All Ords stock.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Share Gainers

Why Champion Iron, Clarity Pharmaceuticals, St Barbara, and Woodside shares are charging higher today

These shares are having a good session today. But why are investors buying them?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why ALS, Black Cat, Boss Energy, and Soul Patts shares are falling today

These shares are falling on Thursday. Let's find out why.

Read more »

A car dealer stands amid a selection of cars parked in a showroom.
Broker Notes

Up 77% in a year, guess how much more upside Macquarie tips for Eagers Automotive shares

Macquarie released its latest analysis on Eagers Automotive fast rising shares this morning.

Read more »

Boy looks quizzical standing in front of a graph.
Share Market News

Big ASX 200 news! Stock market whipsaws as Trump's tariffs struck down

Markets initially surged on news that Trump's tariffs are out.

Read more »

Frustrated and shocked business woman reading bad news online from phone.
Broker Notes

Guess which ASX 200 share Goldman Sachs just downgraded

The broker is calling time on this stock's rally.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Share Market News

5 things to watch on the ASX 200 on Thursday

Here's what to expect on the local market today.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares can rise 20% to 50%

Let's see which shares are being tipped to rocket from current levels.

Read more »